Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study of 22 million seniors tests pneumonia Vaccine's Real-World power

NCT ID NCT06782282

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how effective the Prevnar 20 (PCV20) vaccine is at preventing serious lung infections in people aged 65 and older. Researchers will analyze medical records from over 22 million Medicare beneficiaries, comparing those who got the vaccine to those who did not. The goal is to see if the vaccine reduces cases of pneumonia and other lower respiratory infections in real-world conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Prevnar 20 (20-valent pneumococcal conjugate vaccine, PCV20)
What this could lead to
If successful, this could confirm that the PCV20 vaccine effectively prevents serious lung infections in older adults, supporting its widespread use.
What could go wrong
This is an observational study using existing data, not a controlled trial, so results may be influenced by unmeasured factors. It does not test new treatments or vaccines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

22,234,435 people

The number who actually took part.

Started

Jan 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Aged ≥65 years, residing in one of the 50 US states or in Washington, D.C., continuously enrollmed in Medicare FFS Parts A and B for 365 days prior to the index date, allowing for gaps of ≤45 days (baseline period)

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients from the Medicare database to be included in the analysis must be: * aged 65 or older as of 28Jan22 (date of 20-valent pneumococcal conjugate vaccine (PCV20) * residing in one of the 50 US states or Washington DC * be continuously enrolled in Medicare Fee for Service Parts A and B for 365 days prior to the index date allowing for gaps of up to 45 days (baseline period) Patients from the Medicare database will be excluded from the analysis if: * there is a record of death prior to the index date * the patient was enrolled in Medicare Part C at any point between 28Jan22 and the index date * the patient received PCV20 before 01Jul22 * the patient received PCV15 prior to the index date * sex information is missing If the patient received the pneumococcal polysaccharide vaccine (PPSV23) within 2 years prior to index date, the corresponding time segment (ie 2 years prior to index date) will be excluded. If the patient received PCV13 within the past 5 years prior to the index date, the corresponding time segment (ie 5 years prior to index date) will be excluded. However, those who received PCV13 more than 5 years prior to index date will still have all data included in primary analyses. For PCV20 period, exclude those when IPD, PP, ACP or LRTI outcome incurred between PCV20 vaccination date and prior to the index date (a 30-day blackout period).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Community acquired pneumonia (CAP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Community-Acquired Pneumonia pneumococcal infection prevention target pneumonia prevention target streptococcal pneumonia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Community acquired pneumonia (CAP)

Contacts and locations

Locations

  • Pfizer United States

    New York, New York, 10017, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.